NCT00475956View on ClinicalTrials.gov

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2009

Conditions
Neoplasms
Interventions
DRUG

AZD2171

oral tablet multiple ascending doses 20, 30 or 45 mg

DRUG

AZD0530

oral tablet multiple ascending doses 125 mg or 175 mg

Trial Locations (3)

Unknown

Research Site, Freiburg im Breisgau

Research Site, Essen

Research Site, Herne

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY